Standard Operating Procedure for Governance of High-Risk Submission Programs
| Department | Regulatory Affairs |
| SOP No. | RA/2026/793 |
| Supersedes | NA |
| Page No. | 1 of X |
| Issue Date | 18/04/2026 |
| Effective Date | 18/04/2026 |
| Review Date | 18/04/2028 |
Purpose
This Standard Operating Procedure (SOP) establishes a systematic and controlled approach for governing high-risk submission programs within the Regulatory Affairs function. It aims to ensure compliance with applicable regulatory requirements and internal quality standards, reduce risk of submission errors or delays, and facilitate coordinated cross-functional collaboration thereby enhancing the efficiency and effectiveness of regulatory submissions involving complex or high-impact products or activities.
Scope
This SOP applies to all high-risk regulatory submission programs including but not limited to new drug applications, variations, renewals, and post-approval commitments that are managed or supported by the Regulatory Affairs department. It covers coordination among cross-functional teams such as Quality Assurance, Quality Control, Manufacturing, Clinical, and Compliance. The scope includes preparation, review, approval, submission, tracking, and governance activities related to these high-risk submissions. Routine or low-risk submissions, as defined in associated procedural documents, are excluded from this SOP.
Responsibilities
- Regulatory Affairs Executives: Execute submission-related activities, prepare documentation, and coordinate with cross-functional stakeholders.
- Regulatory Affairs Managers: Review and supervise submission documents, ensure compliance with regulations, and manage timelines.
- Quality Assurance: Verify adherence to GMP and quality standards related to submission documents and processes.
- Cross-Functional Representatives (e.g., Manufacturing, Clinical, QC): Provide required technical inputs and data relevant to submissions.
- Regulatory Operations Coordinators: Track document versions, ensure timely communication, and maintain submission logs.
- Authorized Approvers: Review and approve submissions before filing with regulatory agencies.
Accountability
The Regulatory Affairs Head holds overall accountability for implementation, compliance, periodic review, and escalation of this SOP. They ensure that governance processes for high-risk submission programs are effective, address regulatory requirements, and are periodically evaluated for continuous improvement.
Procedure
The governance of high-risk submission programs shall be conducted through the following detailed procedure:
1. Preparation and Prerequisites: Identify and classify submissions as “high-risk” based on predefined criteria such as complexity, regulatory impact, product novelty, or prior compliance history. Ensure that all necessary cross-functional teams are engaged early in the process.
2. Documentation and Data Collection: Collate all required documents including clinical data, manufacturing records, quality certificates, and validation summaries. Verify data completeness and integrity using checklists specific to the submission type.
3. Cross-Functional Coordination: Schedule and conduct periodic coordination meetings involving all stakeholders to review progress, discuss potential risks, and resolve queries. Maintain meeting minutes and action item logs.
4. Quality and Compliance Review: Perform comprehensive reviews for GMP compliance, regulatory adherence, and data accuracy. QA shall validate that documents meet internal and regulatory standards before submission.
5. Submission Compilation and Approval: Assemble the final dossier ensuring proper format, version control, and document traceability. Obtain formal approval signatures from designated authorized personnel as per the approval matrix.
6. Filing and Tracking: Submit the dossier to the regulatory authority following established submission pathways (electronic or hard copy). Record submission details, dates, and communication references in the submission tracking system.
7. In-Process Controls and Monitoring: Monitor progress of submission review by the agency, promptly address deficiency queries, and document all correspondence.
8. Deviation Handling: Any deviations from the standard process or timelines must be documented using deviation reports and investigated for root cause with corrective actions initiated.
9. Record Retention and Archiving: Maintain all submission-related records in secure repositories according to document retention policies to ensure retrieval capability for audits or inspections.
10. Periodic Review and Continuous Improvement: Conduct scheduled reviews of submission program effectiveness, incorporating lessons learned and updates in regulatory guidelines into the governance process.
This structured procedure provides a transparent, compliant, and consistent governance framework to mitigate risks associated with high-impact regulatory submission programs and enable successful regulatory outcomes.
Abbreviations
- GMP: Good Manufacturing Practice
- QA: Quality Assurance
- QC: Quality Control
- SOP: Standard Operating Procedure
- RA: Regulatory Affairs
- EMA: European Medicines Agency
- FDA: Food and Drug Administration
Documents
Documents required and maintained under this SOP include:
- High-Risk Submission Checklist (Annexure-1)
- Cross-Functional Coordination Meeting Minutes Template (Annexure-2)
- Submission Tracking Log (Annexure-3)
References
- ICH Q10: Pharmaceutical Quality System
- FDA Guidance for Industry – Electronic Submissions
- EU Annex 11: Computerised Systems
- Internal Document Control Policy
- Company Quality Management System Manual
- Relevant Pharmacopoeial Standards
Version
1.0
Approval
| Prepared By | |
| Checked By | |
| Approved By |
Annexures
Annexure-1: High-Risk Submission Checklist
Purpose: To ensure all key elements and data required for a high-risk submission are complete, verified, and compliant before submission.
| Checklist Item | Status (Yes/No) | Comments |
|---|---|---|
| Product and Submission Classification Completed | Yes | Confirmed as high-risk per criteria |
| Clinical Data Included and Verified | Yes | Data matches protocol requirements |
| Manufacturing and Quality Records Included | Yes | Batch records reviewed and attached |
| Validation and Calibration Certificates Attached | Yes | Certificates valid as of 01/02/2026 |
| Labeling and Packaging Specifications Reviewed | Yes | Conforms to latest regulatory guidelines |
| Risk Assessment Conducted | Yes | Mitigation measures documented |
| Cross-Functional Approval Obtained | Yes | Signatures present in submission dossier |
| Regulatory Strategy Document Attached | Yes | Aligned with global submission plan |
Annexure-2: Cross-Functional Coordination Meeting Minutes Template
Purpose: To document discussions, decisions, and action items from coordination meetings held to support high-risk submission governance.
| Meeting Date: | 15/03/2026 |
| Attendees: | Regulatory Affairs, QA, Manufacturing, Clinical, QC, Compliance |
| Agenda: | Submission Status Review, Risk Mitigation, Document Updates |
| Discussion Summary: | Reviewed completeness of dossier, addressed pending data gaps, confirmed timelines. |
| Action Items: |
|
| Next Meeting Date: | 22/03/2026 |
| Minutes Prepared By: | Assigned Regulatory Affairs Executive |
Annexure-3: Submission Tracking Log
Purpose: To maintain an updated log of all activities, communications, and status milestones for high-risk submissions to ensure effective tracking and control.
| Submission ID | Product Name | Submission Type | Submission Date | Regulatory Body | Status | Comments |
|---|---|---|---|---|---|---|
| HRSP-2026-001 | Product A | New Drug Application | 18/04/2026 | FDA | Submitted | On target for review |
| HRSP-2026-002 | Product B | Variation | 10/04/2026 | EMA | Under Review | Additional data requested |
| HRSP-2026-003 | Product C | Renewal | 02/04/2026 | FDA | Approved | Approval letter received 15/04/2026 |
Revision History
| Revision Date | Revision No. | Revision Details | Reason for Revision | Approved By |
| 18/04/2026 | 1.0 | Initial issue | New SOP creation |